Zevra Therapeutics Inc has a share price target of US$ 22, revenue growth forecast of 260.3%, and profit growth estimate of 109.3% for FY25, based on top 8 analyst calls.
Upgrade Your Plan
You need to upgrade your subscription plan to access this feature